卵巢癌中TGF-β驱动的T细胞排斥:对免疫低响应状态的单细胞和空间转录组视图
1Yibin Institute of Traditional Chinese Medicine, Yibin, Sichuan, China.
Frontiers in immunology
|November 3, 2025
概括
转变卵巢癌治疗包括克服TGF-β驱动的障碍. 新的策略将TGF-β洞察与免疫疗法相结合,以改善患上上皮质卵巢癌的患者的治疗结果.
科学领域:
- 瘤学和免疫学
- 分子生物学和遗传学
- 癌症研究 癌症研究
背景情况:
- 表皮卵巢癌 (EOC) 是一种高度致命的恶性瘤,对当前的免疫疗法具有有限的持久反应.
- 瘤微环境,特别是转化生长因子-β (TGF-β) 介导的树皮壁垒和T细胞排斥,限制了免疫疗法的有效性.
- 单细胞分析技术为瘤微环境中的细胞相互作用提供了前所未有的解决方案.
研究的目的:
- 审查了解EOC中TGF-β信号的进展.
- 通过调节TGF-β通路来确定精确免疫瘤学的转化机会.
- 讨论挑战,并概述用于新型策略临床实施的务实标准.
主要方法:
- 单细胞RNA测序 (scRNA-seq) 和ATAC测序 (scATAC-seq) 的整合,以分析细胞程序.
- 空间转录组学的应用用于绘制细胞相互作用和空间生物标志物的地图.
- 对TGF-β信号传导,免疫瘤学和EOC的治疗策略的当前文献的审查和综合.
主要成果:
- TGF-β信号影响纤维细胞,瘤和免疫细胞程序,有助于树突壁壁和T细胞排除.
- 确定了特定的TGF-β信息读数 (例如,INHBA+ CAFs,皮质素,纤维素,MHC-I状态,CD8瘤距离).
- 新兴的策略旨在将TGF-β通路调节与检查点抑制剂相结合,以增强抗瘤免疫力.
结论:
- 调节TGF-β信号传递对增强卵巢上皮癌免疫疗法的疗效具有显著的前景.
- 将TGF-β告知生物标志物和途径抑制剂与基于PD-1的疗法相结合,可以克服治疗耐药性.
- 解决异质性和标准化测试对于精确免疫瘤学方法的成功临床转化至关重要.
相关概念视频
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
01:16TGF - β Signaling Pathway
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...